Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 449

1.

Cell-Free SHOX2 DNA Methylation in Blood as a Molecular Staging Parameter for Risk Stratification in Renal Cell Carcinoma Patients: A Prospective Observational Cohort Study.

Jung M, Ellinger J, Gevensleben H, Syring I, Lüders C, de Vos L, Pützer S, Bootz F, Landsberg J, Kristiansen G, Dietrich D.

Clin Chem. 2019 Jan 9. pii: clinchem.2018.297549. doi: 10.1373/clinchem.2018.297549. [Epub ahead of print]

PMID:
30626634
2.

Handling and Reporting of Pelvic Lymphadenectomy Specimens in Prostate and Bladder Cancer: A Web-based Survey by the European Network of Uropathologists (ENUP).

Prendeville S, Berney DM, Bubendorf L, Compérat E, Egevad L, Hes O, Kristiansen G, Oxley J, van Leenders GJLH, Varma M, van der Kwast T.

Histopathology. 2019 Jan 3. doi: 10.1111/his.13818. [Epub ahead of print]

PMID:
30604878
3.

An overview of translational prostate cancer cohorts for prognostic and predictive studies.

Tolkach Y, Kristiansen G.

Histopathology. 2019 Jan;74(1):161-170. doi: 10.1111/his.13770. Review.

PMID:
30565297
4.

The multikinase inhibitor regorafenib decreases angiogenesis and improves portal hypertension.

Uschner FE, Schueller F, Nikolova I, Klein S, Schierwagen R, Magdaleno F, Gröschl S, Loosen S, Ritz T, Roderburg C, Vucur M, Kristiansen G, Lammers T, Luedde T, Trebicka J.

Oncotarget. 2018 Nov 16;9(90):36220-36237. doi: 10.18632/oncotarget.26333. eCollection 2018 Nov 16.

5.

Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma.

Zhao C, Tolkach Y, Schmidt D, Toma M, Muders MH, Kristiansen G, Müller SC, Ellinger J.

World J Urol. 2018 Nov 28. doi: 10.1007/s00345-018-2575-1. [Epub ahead of print]

PMID:
30488095
6.

Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Egevad L, Judge M, Delahunt B, Humphrey PA, Kristiansen G, Oxley J, Rasiah K, Takahashi H, Trpkov K, Varma M, Wheeler TM, Zhou M, Srigley JR, Kench JG.

Pathology. 2019 Jan;51(1):11-20. doi: 10.1016/j.pathol.2018.10.003. Epub 2018 Nov 23.

PMID:
30477882
7.

Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma.

Müller T, Tolkach Y, Stahl D, Steiner S, Hauser S, Ellinger J, Rabien A, Ralla B, Jung K, Stephan C, Kristiansen G.

Clin Genitourin Cancer. 2018 Oct 23. pii: S1558-7673(18)30427-0. doi: 10.1016/j.clgc.2018.10.008. [Epub ahead of print]

PMID:
30448104
8.

Detailed analysis of adenosine A2a receptor (ADORA2A) and CD73 (5'-nucleotidase, ecto, NT5E) methylation and gene expression in head and neck squamous cell carcinoma patients.

Vogt TJ, Gevensleben H, Dietrich J, Kristiansen G, Bootz F, Landsberg J, Goltz D, Dietrich D.

Oncoimmunology. 2018 Apr 18;7(8):e1452579. doi: 10.1080/2162402X.2018.1452579. eCollection 2018.

PMID:
30221045
9.

tRNA-halves are prognostic biomarkers for patients with prostate cancer.

Zhao C, Tolkach Y, Schmidt D, Muders M, Kristiansen G, Müller SC, Ellinger J.

Urol Oncol. 2018 Nov;36(11):503.e1-503.e7. doi: 10.1016/j.urolonc.2018.08.003. Epub 2018 Sep 9.

PMID:
30209018
10.

The knockdown of the Mediator complex subunit MED15 restrains urothelial bladder cancer cells' malignancy.

Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J.

Oncol Lett. 2018 Sep;16(3):3013-3021. doi: 10.3892/ol.2018.9014. Epub 2018 Jun 25.

11.

[Meeting Report of the Uropathology Working Group of the German Society of Pathology, 2018].

Gaisa NT, Kristiansen G, Wild PJ.

Pathologe. 2018 Dec;39(Suppl 2):344-345. doi: 10.1007/s00292-018-0482-2. German. No abstract available.

PMID:
30120511
12.

CTLA4 methylation predicts response to anti-PD-1 and anti-CTLA-4 immunotherapy in melanoma patients.

Goltz D, Gevensleben H, Vogt TJ, Dietrich J, Golletz C, Bootz F, Kristiansen G, Landsberg J, Dietrich D.

JCI Insight. 2018 Jul 12;3(13). pii: 96793. doi: 10.1172/jci.insight.96793. [Epub ahead of print]

13.

Quantification of Liver Fibrosis at T1 and T2 Mapping with Extracellular Volume Fraction MRI: Preclinical Results.

Luetkens JA, Klein S, Träber F, Schmeel FC, Sprinkart AM, Kuetting DLR, Block W, Uschner FE, Schierwagen R, Hittatiya K, Kristiansen G, Gieseke J, Schild HH, Trebicka J, Kukuk GM.

Radiology. 2018 Sep;288(3):748-754. doi: 10.1148/radiol.2018180051. Epub 2018 Jun 26.

PMID:
29944086
14.

[15th annual conference of the DPKK : Molecular analysis in diagnosis and treatment].

Taubert H, Becker C, Borkowetz A, Seitz G, Kristiansen G, Wach S, Wullich B.

Urologe A. 2018 Jun 22. doi: 10.1007/s00120-018-0710-7. [Epub ahead of print] German. No abstract available.

PMID:
29934648
15.

FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.

Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Sültmann H, Grüllich C, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing S.

Urol Oncol. 2018 Aug;36(8):365.e15-365.e26. doi: 10.1016/j.urolonc.2018.05.020. Epub 2018 Jun 7.

PMID:
29887238
16.

Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.

Zinnall U, Weyerer V, Compérat E, Camparo P, Gaisa NT, Knuechel-Clarke R, Perren A, Lugli A, Toma M, Baretton G, Kristiansen G, Wirtz RM, Cheng L, Wullich B, Stoehr R, Hartmann A, Bertz S.

Hum Pathol. 2018 Oct;80:55-64. doi: 10.1016/j.humpath.2018.05.022. Epub 2018 Jun 6.

PMID:
29885409
17.

Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas.

Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T.

Int J Cancer. 2018 Apr 19. doi: 10.1002/ijc.31547. [Epub ahead of print]

PMID:
29672836
18.

The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells.

Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Müller SC, Kristiansen G, Ellinger J.

Ann Diagn Pathol. 2018 Jun;34:18-26. doi: 10.1016/j.anndiagpath.2017.12.008. Epub 2017 Dec 20.

PMID:
29661722
19.

Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.

Bergheim J, Semaan A, Gevensleben H, Groening S, Knoblich A, Dietrich J, Weber J, Kalff JC, Bootz F, Kristiansen G, Dietrich D.

Br J Cancer. 2018 May;118(9):1217-1228. doi: 10.1038/s41416-018-0035-8. Epub 2018 Apr 3.

PMID:
29610456
20.

Significance of PITX2 Promoter Methylation in Colorectal Carcinoma Prognosis.

Semaan A, Uhl B, Branchi V, Lingohr P, Bootz F, Kristiansen G, Kalff JC, Matthaei H, Pantelis D, Dietrich D.

Clin Colorectal Cancer. 2018 Jun;17(2):e385-e393. doi: 10.1016/j.clcc.2018.02.008. Epub 2018 Feb 23.

PMID:
29580650
21.

Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling.

Roswall P, Bocci M, Bartoschek M, Li H, Kristiansen G, Jansson S, Lehn S, Sjölund J, Reid S, Larsson C, Eriksson P, Anderberg C, Cortez E, Saal LH, Orsmark-Pietras C, Cordero E, Haller BK, Häkkinen J, Burvenich IJG, Lim E, Orimo A, Höglund M, Rydén L, Moch H, Scott AM, Eriksson U, Pietras K.

Nat Med. 2018 May;24(4):463-473. doi: 10.1038/nm.4494. Epub 2018 Mar 12.

22.

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab.

Schwab KS, Kristiansen G, Schild HH, Held SEA, Heine A, Brossart P.

Case Rep Oncol. 2018 Jan 4;11(1):17-20. doi: 10.1159/000485562. eCollection 2018 Jan-Apr.

23.

YRNA expression in prostate cancer patients: diagnostic and prognostic implications.

Tolkach Y, Niehoff EM, Stahl AF, Zhao C, Kristiansen G, Müller SC, Ellinger J.

World J Urol. 2018 Jul;36(7):1073-1078. doi: 10.1007/s00345-018-2250-6. Epub 2018 Feb 28.

PMID:
29492585
24.

Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy.

Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, Hecking T, Keyver-Paik MD, Kaiser C, Ahmadzadehfar H, Essler M, Kuhn W, Kristiansen G.

Breast Cancer Res Treat. 2018 Jun;169(3):447-455. doi: 10.1007/s10549-018-4717-y. Epub 2018 Feb 17.

PMID:
29455299
25.

Quantitative perineural invasion is a prognostic marker in prostate cancer.

Lubig S, Thiesler T, Müller S, Vorreuther R, Leipner N, Kristiansen G.

Pathology. 2018 Apr;50(3):298-304. doi: 10.1016/j.pathol.2017.09.013. Epub 2018 Feb 12.

PMID:
29448999
26.

PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas.

Franzen A, Vogt TJ, Müller T, Dietrich J, Schröck A, Golletz C, Brossart P, Bootz F, Landsberg J, Kristiansen G, Dietrich D.

Oncotarget. 2017 Dec 7;9(1):641-650. doi: 10.18632/oncotarget.23080. eCollection 2018 Jan 2.

27.

Serum miR-122-5p and miR-206 expression: non-invasive prognostic biomarkers for renal cell carcinoma.

Heinemann FG, Tolkach Y, Deng M, Schmidt D, Perner S, Kristiansen G, Müller SC, Ellinger J.

Clin Epigenetics. 2018 Jan 23;10:11. doi: 10.1186/s13148-018-0444-9. eCollection 2018.

28.

Next-generation nuclear morphology to grade solid tumours.

Kristiansen G.

Lancet Oncol. 2018 Mar;19(3):275-277. doi: 10.1016/S1470-2045(18)30063-9. Epub 2018 Feb 3. No abstract available.

29.

The Mediator complex subunit MED15, a promoter of tumour progression and metastatic spread in renal cell carcinoma.

Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J, Syring I.

Cancer Biomark. 2018;21(4):839-847. doi: 10.3233/CBM-170757.

PMID:
29400661
30.

The Heterogeneity of Prostate Cancer: A Practical Approach.

Tolkach Y, Kristiansen G.

Pathobiology. 2018;85(1-2):108-116. doi: 10.1159/000477852. Epub 2018 Jan 31.

PMID:
29393241
31.
32.

[The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer].

Thelen P, Taubert H, Duensing S, Kristiansen G, Merseburger AS, Cronauer MV.

Aktuelle Urol. 2018 Jan 25. doi: 10.1055/s-0043-115426. [Epub ahead of print] German.

PMID:
29370587
33.

Utility of Pathology Imagebase for standardisation of prostate cancer grading.

Egevad L, Delahunt B, Berney DM, Bostwick DG, Cheville J, Comperat E, Evans AJ, Fine SW, Grignon DJ, Humphrey PA, Hörnblad J, Iczkowski KA, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, True LD, Tsuzuki T, van der Kwast T, Varma M, Zhou M, Clements M.

Histopathology. 2018 Jul;73(1):8-18. doi: 10.1111/his.13471. Epub 2018 Mar 5.

PMID:
29359484
34.

Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP).

Kammerer-Jacquet SF, Compérat E, Egevad L, Hes O, Oxley J, Varma M, Kristiansen G, Berney DM.

Virchows Arch. 2018 Apr;472(4):599-604. doi: 10.1007/s00428-017-2265-1. Epub 2018 Jan 11.

PMID:
29327138
35.
36.

Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer.

Kristiansen G.

Mod Pathol. 2018 Jan;31(S1):S143-155. doi: 10.1038/modpathol.2017.168.

37.

Type, Frequency, and Spatial Distribution of Immune Cell Infiltrates in CNS Germinomas: Evidence for Inflammatory and Immunosuppressive Mechanisms.

Zapka P, Dörner E, Dreschmann V, Sakamato N, Kristiansen G, Calaminus G, Vokuhl C, Leuschner I, Pietsch T.

J Neuropathol Exp Neurol. 2018 Feb 1;77(2):119-127. doi: 10.1093/jnen/nlx106.

PMID:
29237087
38.

DNA Methylation Analysis of Free-Circulating DNA in Body Fluids.

Jung M, Kristiansen G, Dietrich D.

Methods Mol Biol. 2018;1708:621-641. doi: 10.1007/978-1-4939-7481-8_32.

PMID:
29224167
39.

Exome sequencing characterizes the somatic mutation spectrum of early serrated lesions in a patient with serrated polyposis syndrome (SPS).

Horpaopan S, Kirfel J, Peters S, Kloth M, Hüneburg R, Altmüller J, Drichel D, Odenthal M, Kristiansen G, Strassburg C, Nattermann J, Hoffmann P, Nürnberg P, Büttner R, Thiele H, Kahl P, Spier I, Aretz S.

Hered Cancer Clin Pract. 2017 Nov 29;15:22. doi: 10.1186/s13053-017-0082-9. eCollection 2017.

40.

Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients.

de Vos L, Gevensleben H, Schröck A, Franzen A, Kristiansen G, Bootz F, Dietrich D.

Clin Epigenetics. 2017 Dec 1;9:125. doi: 10.1186/s13148-017-0425-4. eCollection 2017.

41.

Diagnostic accuracy of [99mTc]Tc-Sestamibi in the assessment of thyroid nodules.

Yordanova A, Mahjoob S, Lingohr P, Kalff J, Türler A, Palmedo H, Biersack HJ, Kristiansen G, Farahati J, Essler M, Ahmadzadehfar H.

Oncotarget. 2017 Oct 17;8(55):94681-94691. doi: 10.18632/oncotarget.21866. eCollection 2017 Nov 7.

42.

Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations.

Egevad L, Delahunt B, Kristiansen G, Samaratunga H, Varma M.

Pathology. 2018 Jan;50(1):60-73. doi: 10.1016/j.pathol.2017.09.008. Epub 2017 Dec 6. Review.

PMID:
29199015
43.

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.

Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grüllich C, Jäger D, Sültmann H, Duensing A, Perner S, Cronauer MV, Stephan C, Debus J, Schrader AJ, Kristiansen G, Hohenfellner M, Duensing S.

Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1.

PMID:
29198908
44.

Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology.

Hecking T, Thiesler T, Schiller C, Lunkenheimer JM, Ayub TH, Rohr A, Condic M, Keyver-Paik MD, Fimmers R, Kirfel J, Kuhn W, Kristiansen G, Kübler K.

Oncotarget. 2017 Oct 6;8(54):92890-92903. doi: 10.18632/oncotarget.21641. eCollection 2017 Nov 3.

45.

The Contrasting Role of the Mediator Subunit MED30 in the Progression of Bladder Cancer.

Syring I, Weiten R, Müller T, Schmidt D, Steiner S, Kristiansen G, Müller SC, Ellinger J.

Anticancer Res. 2017 Dec;37(12):6685-6695.

PMID:
29187445
46.

YRNA expression predicts survival in bladder cancer patients.

Tolkach Y, Stahl AF, Niehoff EM, Zhao C, Kristiansen G, Müller SC, Ellinger J.

BMC Cancer. 2017 Nov 10;17(1):749. doi: 10.1186/s12885-017-3746-y.

47.

Low BUB1 expression is an adverse prognostic marker in gastric adenocarcinoma.

Stahl D, Braun M, Gentles AJ, Lingohr P, Walter A, Kristiansen G, Gütgemann I.

Oncotarget. 2017 Jul 18;8(44):76329-76339. doi: 10.18632/oncotarget.19357. eCollection 2017 Sep 29.

48.

Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression.

Bläsius FM, Meller S, Stephan C, Jung K, Ellinger J, Glocker MO, Thiesen HJ, Tolkach Y, Kristiansen G.

Oncotarget. 2017 Aug 24;8(43):75076-75086. doi: 10.18632/oncotarget.20507. eCollection 2017 Sep 26.

49.

[Meeting Report of the Working Group on Uropathology of the German Society of Pathology].

Wild PJ, Kristiansen G.

Pathologe. 2017 Nov;38(Suppl 2):245-246. doi: 10.1007/s00292-017-0368-8. German. No abstract available.

PMID:
29046947
50.

Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?

Zhao Z, Stephan C, Weickmann S, Jung M, Kristiansen G, Jung K.

Int J Mol Sci. 2017 Sep 21;18(10). pii: E2023. doi: 10.3390/ijms18102023. Review.

Supplemental Content

Loading ...
Support Center